Cai‐Jin Lin

Shanghai Medical College of Fudan University — China

Medicine · Health Sciences

14h-index619citations66works5.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(27), Breast Cancer Treatment Studies(22), Advanced Breast Cancer Therapies(16), Cancer Genomics and Diagnostics(11), Breast Lesions and Carcinomas(10)

Publications66 total

Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities
UNC Libraries·2025Open Access
Landscape of gene fusions in hormone receptor-positive breast cancer reveals ADK fusions as drivers of progression and potential therapeutic targets
Cell Discovery·2025Open Access
Precision treatment in breast cancer: Leveraging genetic interactions
Clinical and Translational Medicine·2025Open Access
Kinesin-like protein KIFC2 stabilizes CDK4 to accelerate growth and confer resistance in HR+/HER2– breast cancer
Journal of Clinical Investigation·2025· 2 citedOpen Access
Multi-omics profile of exceptional long-term survivors of AJCC stage III triple-negative breast cancer
Chinese Journal of Cancer Research·2025Open Access
Genomic spectra of lymphovascular invasion in breast cancer
Chinese Journal of Cancer Research·2025Open Access
Table S3 from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2024Open Access
Figure S2 from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2024Open Access
Figure S3 from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2024Open Access
Table S2 from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2024Open Access
Figure S7 from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2024Open Access
Table S4 from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2024Open Access
Table S1 from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2024Open Access
Table S5 from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2024Open Access
Figure S6 from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2024Open Access
Supplemental Materials and Methods from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2024Open Access
Figure S1 from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2024Open Access
Figure S4 from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2024Open Access
Figure S5 from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2024Open Access
Data from Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
2024· 1 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Zhi‐Ming Shao(19), Xi Jin(17), Yi‐Zhou Jiang(17), Jiayi Wu(15), Li Zhu(15), Kunwei Shen(14), Yi-Fan Zhou(13), Lei-Jie Dai(12), Wentao Yang(12), Shuning Ding(12), Ding Ma(11), Weiguo Chen(10), Lisa Andriani(9), Xiangrong Wu(8), Shen Zhao(8), Yi Xiao(8), Ying Wang(8), Chenglin Liu(7), Jinxiu Shi(7), Xiaosong Chen(7)